109.67

0.32% -0.1819

Jazz Pharmaceuticals plc (JAZZ)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$109.85

Aprire:

$109.5

Volume 24 ore:

288.11K

Capitalizzazione di mercato:

$6.92B

Reddito:

$3.83B

Utile/perdita netta:

$414.83M

Rapporto P/E:

-69.85

EPS:

-1.57

Flusso di cassa netto:

$1.05B

1 W Prestazione:

-1.13%

1M Prestazione:

-5.94%

6M Prestazione:

-18.08%

1 anno Prestazione:

-21.45%

Intervallo 1D:

$108.60

$110.48

Portata 52W:

$103.01

$146.70

Jazz Pharmaceuticals plc Stock (JAZZ) Company Profile

Nome

Jazz Pharmaceuticals plc

Settore

Healthcare (1219)

Industria

Biotechnology (700)

Telefono

353 1 634 7800

Indirizzo

Waterloo Exchange, Fifth Floor Waterloo Road, Dublin

Dipendente

1,290

Cinguettio

@jazzpharma

Prossima data di guadagno

2024-05-15

Ultimi documenti SEC

JAZZ's Discussions on Twitter

Jazz Pharmaceuticals plc Stock (JAZZ) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-03	Iniziato	Robert W. Baird	Outperform
2023-11-27	Downgrade	UBS	Buy → Neutral
2023-09-29	Iniziato	Raymond James	Mkt Perform
2023-06-12	Ripresa	Wells Fargo	Equal Weight
2022-12-09	Aggiornamento	Goldman	Neutral → Buy
2022-06-14	Iniziato	UBS	Buy
2022-04-06	Downgrade	Goldman	Buy → Neutral
2021-11-19	Ripresa	Goldman	Buy
2021-10-07	Ripresa	Jefferies	Buy
2021-10-05	Iniziato	Citigroup	Buy
2021-09-23	Iniziato	Needham	Buy
2021-05-19	Ripresa	JP Morgan	Overweight
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-02-05	Reiterato	H.C. Wainwright	Buy
2021-02-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-01-29	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-12-16	Iniziato	UBS	Buy
2020-11-03	Reiterato	H.C. Wainwright	Buy
2020-10-09	Reiterato	H.C. Wainwright	Buy
2020-09-14	Downgrade	Goldman	Neutral → Sell
2020-09-14	Ripresa	JP Morgan	Overweight
2020-08-06	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-07-28	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2020-07-23	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-04-06	Iniziato	Jefferies	Buy
2020-03-12	Aggiornamento	Bernstein	Mkt Perform → Outperform
2020-01-08	Iniziato	Goldman	Neutral
2019-08-21	Downgrade	Piper Jaffray	Overweight → Neutral
2019-06-11	Iniziato	Barclays	Overweight
2019-03-20	Iniziato	SunTrust	Buy
2018-12-14	Iniziato	Wolfe Research	Peer Perform
2018-11-08	Reiterato	B. Riley FBR	Buy
2018-08-08	Reiterato	Stifel	Buy
2018-07-11	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2018-03-23	Reiterato	H.C. Wainwright	Neutral
2018-03-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight

Mostra tutto

Jazz Pharmaceuticals plc Borsa (JAZZ) Ultime notizie

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

Jazz Pharmaceuticals plc Azioni (JAZZ) Dati Finanziari

Jazz Pharmaceuticals plc (JAZZ) Reddito 2024

JAZZ ha riportato un ricavo (TTM) di $3.83 miliardi per il trimestre terminato il 2023-12-31, un +4.78% salita anno su anno.

Jazz Pharmaceuticals plc (JAZZ) Reddito netto 2024

JAZZ l'utile netto (TTM) è stato di $414.83 milioni per il trimestre terminato il 2023-12-31, un +285.14% aumento anno su anno.

Jazz Pharmaceuticals plc (JAZZ) Flusso di cassa 2024

JAZZ ha registrato un flusso di cassa disponibile (TTM) di $1.05 miliardi per il trimestre conclusosi con 2023-12-31, un +35.57% aumento anno su anno.

Jazz Pharmaceuticals plc (JAZZ) Utile per azione 2024

L'utile per azione (TTM) di JAZZ è stato pari a $6.12 per il trimestre terminato il 2023-12-31, un +272.39% crescita anno su anno.

Jazz Pharmaceuticals plc Azioni (JAZZ) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Carr Patricia	SVP, Chief Accounting Officer	Mar 06 '24	Sale	119.64	1,936	231,628	8,364
Johnson Philip L	EVP & Chief Financial Officer	Mar 01 '24	Buy	119.65	12,000	1,435,800	27,932
Cook Jennifer E.	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888
Smith Mark Douglas	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888
Patil Neena M	EVP & Chief Legal Officer	Sep 01 '23	Sale	144.25	1,500	216,375	29,186
Carr Patricia	SVP, Chief Accounting Officer	Aug 29 '23	Sale	143.47	142	20,373	5,986
Patil Neena M	EVP & Chief Legal Officer	Aug 15 '23	Sale	139.59	750	104,695	30,686
McSharry Heather Ann	Director	Aug 14 '23	Sale	138.16	1,344	185,685	16,778
Sohn Catherine A.	Director	Aug 14 '23	Sale	138.16	1,241	171,455	14,868
ENRIGHT PATRICK G	Director	Aug 14 '23	Sale	138.16	1,241	171,455	20,946